Germany-based precision surgery platform Caresyntax has raised $180m in a series C extension round, which comprises $80m of equity and up to $100m of growth debt facility.
Participants in the investment round include Symbiotic Capital, MTIP, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, BlackRock Innovation Capital, and surgical.ai.
In addition, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance, also participated in the round.
Caresyntax intends to use the financing for scaling customer adoption of surgical software tools, continued development of its AI and cloud applications, and support its M&A strategy.
Caresyntax CFO and CBO Bjoern von Siemens said: “We are grateful for this significant investment in Caresyntax, which strengthens our balance sheet at an important inflection point for the adoption of digital surgery, AI and automation tools.
“The capital enables Caresyntax to deliver increased growth momentum, platform adoption and customer ROI; it also catalyzes M&A and corporate development opportunities.”
Caresyntax leverages technology and AI to collect, integrate, and analyse unique and comprehensive data, providing caregivers with real-time and long-term clinical decision support.
The company aims to enhance the patient journey, increase the operational efficiency of the hospital and drive better patient outcomes and profitability.
Caresyntax offers a scalable, medical-grade, interoperable end-to-end software, and AI platform, which enhances surgical precision and patient safety.
The platform also addresses critical data shortage and fragmentation challenges that delay the progress of precision and data-assisted surgery in the global surgical market.
Caresyntax co-founder and CEO Dennis Kogan said: “Together with our partners and investors, we are working towards deploying precision surgical tools, empowered by data and AI, to improve patient outcomes.
“This financing is not just an investment in Caresyntax, but an investment in the future of surgery. My gratitude extends to our investors who contribute to and believe in the power of smart data and AI usage in the operating room.”
